High-risk estrogen-receptor-positive breast cancer: identification and implications for therapy.
The estrogen receptor (ER) has long been recognized as a key discriminative feature of breast cancer, which carries profound implications for management. However, recent advances in the understanding of breast cancer heterogeneity have demonstrated the importance of biologic context to the interpretation of ER as a prognostic and predictive factor. The use of tumor subtyping methods and prognostic indicators based on molecular profiling of tumor tissue is now helping to delineate high-risk ER-positive cancer types that have distinct risk and treatment response profiles. These new approaches to breast cancer classification will have a major impact on the conduct of clinical trials and individual patient assessment in the future.
Translational Oncology, Sydney West Cancer Network, Western Sydney and Nepean Blue Mountains Local Health Districts, Sydney, NSW, Australia. rosemary.balleine@sydney.edu.au
Rosemary L
RL
Balleine
Nicholas R
NR
Wilcken
D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D011379:Prognosis; D011960:Receptors, Estrogen / Q000235:genetics / Q000378:metabolism*
D011960:Receptors, Estrogen